

#### Press Release

#### Ransh Pharma Private Limited

July 21, 2022



## **Rating Downgraded**

Product	Quantum (Rs. Cr)	Long Term Rating	Short Term Rating
Bank Loan Ratings	10.00	ACUITE D   Downgraded	-
Total Outstanding Quantum (Rs. Cr)	10.00	-	-
Total Withdrawn Quantum (Rs. Cr)	0.00	-	-

#### Rating Rationale

Acuité has downgraded the long term rating to 'ACUITE D' (read as ACUITE D) from 'ACUITE B' (read as ACUITE B) on the Rs. 10.00 Cr bank facilities of Ransh Pharma Private Limited (RPPL).

The downgrade is on account of the feedback received from the banker that the account had delays in the repayment of principal and interest on the term loan.

#### **About the Company**

Incorporated in 2018, RPPL is a Visakhapatnam based company promoted by Mr Radha Krishna Talam, Mr Karri Adi Krishna Rao, Mr V Nageswar Rao, Mr K Gowri Sankara Rao, Mr. K Poorna Chandra Rao and Mr. K. Narasinga Rao. RPPL is engaged in manufacturing of bulk drugs and pharmaceutical intermediates and has set up a manufacturing unit in Visakhapatnam.

#### **Analytical Approach**

Acuité has considered the standalone business and financial risk profiles of RPPL to arrive at the rating.

#### **Key Rating Drivers**

## **Strengths**

## • Experienced management

Mr. Radha Krishna Talam possesses more than seventeen years of experience in the pharmaceuticals industry. He has been associated with Vasudha Pharma Chem Limited, Visakhapatnam for three years and before that worked for Aurobindo Pharma Limited, Hyderabad for twelve years. Mr. Adi Krishna Rao Karri has been associated with the industry for more than twenty years in managing various projects and the pharmaceuticals products and intermediaries. Acuité believes that promoter's experience in the industry is expected to support in the stabilization of operations.

#### Weaknesses

## Delays in servicing debt obligations

RPPL has been facing significant liquidity pressure which has impeded its ability to meet its debt obligation in a timely manner.

## • Intense competition and fragmented industry

The pharmaceutical formulations industry has a large number of players, which makes this industry highly fragmented and intensely competitive. Hence, limiting RPPL's bargaining power and pricing pressure due to the presence of well-established and large players.

## **Rating Sensitivities**

- Stretched liquidity
- Ongoing delays in debt servicing

#### Material covenants

None

#### **Liquidity Position: Stretched**

RPPL's liquidity is currently stretched as the company has not been able to service its current and maturing debt obligations. Acuité expects the company's liquidity profile to remain stretched over the medium term due to persistent delays in servicing debt obligations.

## Outlook: Stable Not Applicable

#### **Key Financials**

Particulars	Unit	FY 21 (Provisional)	FY 20 (Actual)
Operating Income	Rs. Cr.	0.86	0.00
PAT	Rs. Cr.	(1.22)	0.00
PAT Margin	(%)	(142.52)	0.00
Total Debt/Tangible Net Worth	Times	2.14	1.82
PBDIT/Interest	Times	(0.75)	(176.75)

# Status of non-cooperation with previous CRA (if applicable) None

## Any other information

None

#### **Applicable Criteria**

- Default Recognition https://www.acuite.in/view-rating-criteria-52.htm
- Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm
- Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm

#### Note on complexity levels of the rated instrument

https://www.acuite.in/view-rating-criteria-55.htm

#### **Rating History**

Date	Name of Instruments/Facilities	Term	Amount (Rs. Cr)	Rating/Outlook
08 Nov 2021	Term Loan	Long Term	10.00	ACUITE B   Stable (Reaffirmed)
04 Sep 2020	Term Loan	Long Term	10.00	ACUITE B   Stable (Reaffirmed)
12 Jun 2019	Proposed Term Loan	Long Term	10.00	ACUITE B   Stable (Assigned)

## Annexure - Details of instruments rated

Lender's Name	ISIN	Facilities	Date Of Issuance	Coupon Rate	Maturity Date	Quantum (Rs. Cr.)	Rating
Small Industries Development Bank of India	Not Applicable	Term Loan	20-06- 2019	10.25	Not available	10.00	ACUITE D   Downgraded ( from ACUITE B )

#### Contacts

Analytical	Rating Desk
Pooja Ghosh Vice President-Rating Operations Tel: 022-49294041 pooja.ghosh@acuite.in	Varsha Bist Senior Manager-Rating Operations Tel: 022-49294011 rating.desk@acuite.in
Geeta Karira Analyst-Rating Operations Tel: 022-49294065 geeta.karira@acuite.in	

## About Acuité Ratings & Research

Acuité is a full-service Credit Rating Agency registered with the Securities & Exchange Board of India (SEBI). The company received RBI Accreditation as an External Credit Assessment Institution (ECAI) for Bank Loan Ratings under BASEL-II norms in the year 2012. Acuité has assigned ratings to various securities, debt instruments and bank facilities of entities spread across the country and across a wide cross section of industries. It has its Registered and Head Office in Kanjurmarg, Mumbai.

**Disclaimer:** An Acuité rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. Ratings assigned by Acuité are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, Acuité, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. Acuité is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind, arising from the use of its ratings. Ratings assigned by Acuité are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website (www.acuite.in) for the latest information on any instrument rated by Acuité.